Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Arcturus Therapeutics Holdings Inc.

< Previous 1 2 3 Next >
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces Third Quarter 2021 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Report Third Quarter 2021 Financial Results and Provide Corporate Update on November 8, 2021
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces Leadership Appointments
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 3b Study for ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces Meeting with President of Vietnam and CEO of Vingroup to Discuss Expansion of COVID-19 Vaccine Collaboration
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Participate in Citi's 16th Annual BioPharma Virtual Conference 2021
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces Second Quarter 2021 Financial Results and mRNA Vaccine and Therapeutics Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.